ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Prevnar 20 (pneumococcal 20-valent conjugate vaccine) for Adults Ages 18 Years or Older
June 11, 2021Pfizer Inc. (NYSE:PFE) announced today that FDA has approved Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae serotypes in the vaccine. -
FDA okays Pfizer's Prevnar 20 pneumococcal conjugate vaccine
June 09, 2021Pfizer announced Tuesday that the FDA approved Prevnar 20 to prevent invasive disease and pneumonia caused by 20 Streptococcus pneumoniae serotypes in adults.
Pharma Sources Insight January 2025
